SBIO - ETF AI Analysis
Top Page
ALPS Medical Breakthroughs ETF (SBIO)
Rating:52Neutral
Price Target:―
Positive Factors
Strong Recent Fund Performance
The ETF has shown solid gains so far this year and over the past month, indicating positive recent momentum.
Top Holdings with Strong Gains
Several of the largest positions, including multiple biotech names, have delivered strong year-to-date performance, helping drive the fund higher.
Targeted Exposure to Medical Breakthroughs
The fund focuses entirely on health care and medical innovation companies, giving investors concentrated exposure to a high-growth theme.
Negative Factors
Single-Sector Concentration
With all assets in the health care sector, the ETF is highly exposed to swings in biotech and medical stocks, which can be volatile.
U.S.-Only Geographic Exposure
All holdings are in U.S. companies, so investors do not get diversification across different countries or regions.
Moderate Expense Ratio
The fund’s fee is higher than many broad-market ETFs, which can slightly reduce long-term returns for buy-and-hold investors.
SBIO vs. SPDR S&P 500 ETF (SPY)
AUM190.42M
RegionNorth America
Expense Ratio0.50%
Beta1.15
IssuerALPS
Inception DateDec 31, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedS-Network Medical Breakthroughs Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume51,891
30 Day Avg. Volume33,978
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
104.17Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering103
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SBIO Summary
SBIO is the ALPS Medical Breakthroughs ETF, which follows the S-Network Medical Breakthroughs Index and focuses on smaller U.S. biotech companies working on new drugs and treatments, especially those in later-stage clinical trials. It holds many fast-growing health care names, including Alkermes and Apellis Pharmaceuticals. Someone might invest in SBIO to seek long-term growth from cutting-edge medical innovations and to get diversified exposure to many biotech firms instead of picking single stocks. A key risk is that biotech shares can be very volatile and may rise or fall sharply based on drug trial results and regulatory decisions.
How much will it cost me?The ALPS Medical Breakthroughs ETF (SBIO) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed and focuses on specialized biotechnology companies, which require more research and expertise to manage effectively.
What would affect this ETF?The ALPS Medical Breakthroughs ETF (SBIO) could benefit from increased demand for innovative health care solutions and advancements in biotechnology, especially as its holdings focus on companies developing groundbreaking treatments in clinical trials. However, the ETF may face challenges from regulatory hurdles, high research and development costs, or broader economic pressures that could impact small to mid-cap biotech firms. Changes in interest rates or shifts in investor sentiment toward riskier assets could also influence its performance.
SBIO Top 10 Holdings
SBIO is a pure-play bet on U.S. biotech upstarts, and a handful of names are doing most of the heavy lifting. Apogee Therapeutics and CG Oncology have been rising on the back of upbeat trial news, helping power the fund’s recent momentum. Travere Therapeutics and Edgewise are also pulling their weight, adding steady gains as investors warm to their pipelines. On the flip side, ACADIA looks a bit tired, lagging after a softer stretch. With nearly everything tied to health care innovation, this ETF lives and dies by small- and mid-cap drug developers.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Apogee Therapeutics | 4.36% | $8.30M | $6.81B | 220.56% | 49 Neutral | |
| CG Oncology, Inc. | 3.33% | $6.34M | $5.39B | 158.18% | 58 Neutral | |
| Xenon | 3.09% | $5.89M | $5.11B | 73.99% | 48 Neutral | |
| Oruka Therapeutics | 3.05% | $5.81M | $4.36B | 683.30% | 41 Neutral | |
| Dianthus Therapeutics | 2.83% | $5.39M | $4.51B | 407.96% | 61 Neutral | |
| Travere Therapeutics | 2.80% | $5.34M | $5.13B | 280.33% | 56 Neutral | |
| Definium Therapeutics | 2.73% | $5.19M | $2.67B | 451.84% | 40 Neutral | |
| Veradermics, Incorporated | 2.72% | $5.19M | $3.92B | ― | ― | |
| Edgewise Therapeutics | 2.32% | $4.42M | $3.96B | 157.40% | 40 Underperform | |
| ACADIA Pharmaceuticals | 2.30% | $4.37M | $3.70B | -1.73% | 75 Outperform |
SBIO Technical Analysis
Positive
―
Price Trends
55.09
Positive
53.42
Positive
49.99
Positive
Market Momentum
3.03
Negative
75.05
Negative
89.04
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SBIO, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 56.84, equal to the 50-day MA of 55.09, and equal to the 200-day MA of 49.99, indicating a bullish trend. The MACD of 3.03 indicates Negative momentum. The RSI at 75.05 is Negative, neither overbought nor oversold. The STOCH value of 89.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBIO.
SBIO Peer Comparison
Comparison Results
Performance Comparison
SBIO
ALPS Medical Breakthroughs ETF
64.90
34.64
114.47%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
PBE
Invesco Dynamic Biotechnology & Genome ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents